Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes
Background and Aim The epithelial–mesenchymal transition (EMT) of hepatocytes is a key step for hepatic fibrosis and cirrhosis. Long‐term administration of celecoxib, a selective cyclooxygenase‐2 (COX‐2) inhibitor, can ameliorate hepatic fibrosis. This research aimed to examine the effect of celecox...
Saved in:
Published in | Journal of gastroenterology and hepatology Vol. 29; no. 11; pp. 1932 - 1942 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Blackwell Publishing Ltd
01.11.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background and Aim
The epithelial–mesenchymal transition (EMT) of hepatocytes is a key step for hepatic fibrosis and cirrhosis. Long‐term administration of celecoxib, a selective cyclooxygenase‐2 (COX‐2) inhibitor, can ameliorate hepatic fibrosis. This research aimed to examine the effect of celecoxib on the EMT of hepatocytes during the development of liver cirrhosis.
Methods
Cirrhotic liver model of rat was established by peritoneal injection of thiacetamide (TAA). Thirty‐six rats were randomly assigned to control, TAA, and TAA + celecoxib groups. Hepatic expressions of tumor necrosis factor‐α (TNF‐α), interleukin 6 (IL‐6), COX‐2, prostaglandin E2 (PGE2), matrix metalloproteinase (MMP)‐2 and ‐9, transforming growth factor‐β1 (TGF‐β1), Phospho‐Smad2/3, Snail1, α‐smooth muscle actin (α‐SMA), vimentin, collagen I, fibroblast‐specific protein (FSP‐1), E‐cadherin and N‐cadherin were quantitated. Hepatic fibrosis was assessed by the visible hepatic fibrotic areas and Ishak's scoring system.
Results
Exposed to TAA treatment, hepatocytes underwent the process of EMT during hepatic fibrosis. Compared with those in TAA group, celecoxib significantly downregulated the hepatic expressions of TNF‐α, IL‐6, COX‐2, PGE2, MMP‐2, MMP‐9, TGF‐β1, Phospho‐Smad2/3, Snail1, α‐SMA, FSP‐1, and vimentin while greatly restoring the levels of E‐cadherin. The fibrotic areas and collagen I levels of TAA + celecoxib group were much lower than those in TAA group.
Conclusions
Celecoxib could ameliorate hepatic fibrosis and cirrhosis in TAA‐rat model through suppression of the mesenchymal biomarkers in the hepatocytes while restoring the levels of their epithelial biomarkers. The inhibitory effect of celecoxib on the EMT of hepatocytes is associated with reduction of intrahepatic inflammation, preservation of normal basement matrix, and inhibition of TGF‐β1/Smad pathway. |
---|---|
Bibliography: | istex:CBBABCB69E6A7535289F8E783E6AEB9D443A49BC ArticleID:JGH12641 ark:/67375/WNG-TLFP0H7J-7 Table S1 Primers list for quantitative polymerase chain reaction analysis. Table S2 Effects of celecoxib on the hepatic and renal functions. Natural Science Fund of China - No. 81170413 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0815-9319 1440-1746 |
DOI: | 10.1111/jgh.12641 |